Drugs / Corticosteroids
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT02603575 | Nov 2015 → Dec 2020 | pneumocystosis | Beijing Chao Yang Hospital | Unknown | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 2 | NCT05669001 Background | Dec 2023 → Apr 2026 | — | ITB-Med LLC | Completed | No outcome recorded |
| Phase 2 | NCT06019507 Background | Jun 2022 → Jun 2026 overdue | — | ITB-Med LLC | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03605654 Background | Dec 2024 → Sep 2026 | transplant rejection | Medeor Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/3 | NCT00729768 Background | — | — | Genentech, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01843348 Background | Dec 2012 → Mar 2016 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01625377 Background | Dec 2012 → Mar 2015 | — | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00626197 Background | Feb 2008 → Oct 2009 | lupus nephritis, systemic lupus erythematosus | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00622869 Background | Jan 2008 → Apr 2012 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT04849533 Comparator | Apr 2021 → Jul 2023 | transplant rejection | University of Cincinnati | Unknown | No outcome recorded |
| Phase 4 | NCT00758602 Background | Sep 2008 → Feb 2011 | — | Hoffmann-La Roche | Completed | Missed primary |
| Phase 4 | NCT00634920 Background | Mar 2008 → May 2013 | impaired renal function disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | corticosteroids | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04849533 ↗ |
| Route | Intravenous | “Intravenous and oral repeating dose” NCT00626197 ↗ |
| Route | Oral | “Intravenous and oral repeating dose” NCT00626197 ↗ |